SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer
Cancer · 2024
DOI: 10.1002/cncr.35243 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer, 2024. Verfasst von Sandip P Patel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University of California San Diego Moores Cancer Center, La Jolla, California, USA. Hauptthemen laut MEDLINE: Gallbladder Neoplasms, Ipilimumab, Nivolumab, CTLA-4 Antigen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Bristol-Myers Squibb.
Abstract (Originalsprache)
Introduction
Most patients with advanced gallbladder cancer are treated with multiagent chemotherapy. Immune checkpoint inhibitors offer the possibility of a durable response with less toxicity. This prospective, multicenter, open‐label study was designed to evaluate the anticancer activity of nivolumab plus ipilimumab in patients with advanced gallbladder cancer.
Methods
Nineteen patients with advanced gallbladder cancer refractory to ≥1 previous therapy received nivolumab 240 mg intravenously every 2 weeks and ipilimumab 1 mg/kg intravenously every 6 weeks until disease progression or unacceptable toxicity. The primary end point was confirmed radiographic overall response rate (ORR) (complete response [CR] + partial response [PR] confirmed on subsequent scan); secondary end points included unconfirmed overall response, clinical benefit rate (confirmed and unconfirmed responses + stable disease >6 months), progression‐free survival, overall survival, and toxicity.
Results
The confirmed ORR was 16% (CR, n = 1 [5%]; PR, n = 2 [11%]); all were microsatellite stable, and the confirmed CR had undetectable programmed death‐ligand 1 by immunohistochemistry. The unconfirmed ORR and clinical benefit rates were both 32%. The median duration of response was 14.8 months (range, 4–35.1+ months). The 6‐month progression‐free survival was 26% (95% CI, 12–55). The median overall survival was 7.0 months (95% CI, 3.9–19.1). The most common toxicities were fatigue (32%), anemia (26%), and anorexia (26%). Aspartate aminotransferase elevation was the most common grade 3/4 toxicity (11%). There was 1 possibly related death (sepsis with attendant hepatic failure).
Conclusions
Ipilimumab plus nivolumab was well tolerated and showed modest efficacy with durable responses in previously treated patients with advanced gallbladder cancer. Clinical Trial Registration NCT02834013 ( ClincialTrials.gov ). Plain Language Summary This prospective study assessed the efficacy and safety of nivolumab plus ipilimumab in 19 patients with advanced gallbladder cancer refractory to previous therapy. The combination demonstrated modest efficacy with a 16% confirmed overall response rate, durable responses, and manageable toxicities, suggesting potential benefits for this challenging patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, University of California San Diego Moores Cancer Center, La Jolla, California, USA.
- St. Martin's University, Lacey, Washington, USA.
- Division of Medical Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Division of Hematology/Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Division of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, Illinois, USA.
- Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Sandip P Patel, Young Kwang Chae, Michael J Dennis, Thomas J George, Elad Sharon, Gabby Lopez
Förderung
- NCI NIH HHS
- NIH HHS
- Bristol-Myers Squibb
- National Institutes of Health
Zitieren
APA
Patel, S. P., Guadarrama, E., Chae, Y. K., Dennis, M. J., Powers, B. C., Liao, C. Y., Ferri, W. A., George, T. J., Sharon, E., Ryan, C. W., Othus, M., Lopez, G., Blanke, C. D., & Kurzrock, R. (2024). SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer. Cancer. https://doi.org/10.1002/cncr.35243
Vancouver
Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, et al. SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer. Cancer. 2024. doi:10.1002/cncr.35243
BibTeX
@article{Patel2024,
author = {Patel, Sandip P and Guadarrama, Elizabeth and Chae, Young Kwang and Dennis, Michael J and Powers, Benjamin C and Liao, Chih-Yi and Ferri, William A and George, Thomas J and Sharon, Elad and Ryan, Christopher W and Othus, Megan and Lopez, Gabby and Blanke, Charles D and Kurzrock, Razelle},
title = {SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35243}
}
EUVIMED